Re­gen­eron joins $100M round for DNAnexus and its cloud-com­put­ing DNA soft­ware

DNAnexus has been ac­cru­ing cap­i­tal and cus­tomers for over a decade, since the DNA com­put­ing com­pa­ny spun out of Stan­ford in 2009. Now, two years af­ter their last fund­ing round, the com­pa­ny has raised its largest round yet, at $100 mil­lion, and se­cured what may be its most in­trigu­ing in­vestor: Re­gen­eron Phar­ma­ceu­ti­cals.

Us­ing Ama­zon Web Ser­vices, DNAnexus pro­vides a plat­form for re­searchers, reg­u­la­tors and com­pa­nies to host and an­a­lyze their in­creas­ing­ly large sets of ge­nom­ic da­ta. In 2014, Re­gen­eron was one of the ma­jor biotechs to part­ner with the com­pa­ny. They signed a deal to use DNAnexus’s plat­form cloud-com­put­ing soft­ware for trans­la­tion­al work at the Re­gen­eron Ge­net­ics Cen­ter, in­clud­ing by al­low­ing the cen­ter to com­bine de-iden­ti­fied DNA sam­ples with de-iden­ti­fied clin­i­cal in­for­ma­tion from health­care providers to guide drug dis­cov­ery.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER